Results 171 to 180 of about 11,219 (248)

Breaking chains: IMAAVY redefines generalized myasthenia gravis treatment. [PDF]

Ann Med Surg (Lond)
Shahid K, Shahid SR, Khalid M, Waafira A.   +3 more
europepmc   +1 more source

Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod. [PDF]

BMC Neurol
Fu J, Zheng X, Ma X, Qu Q, Cui W, Mao X, Fu W, Lyv H.   +7 more
europepmc   +1 more source

Rituximab in New-Onset Generalized Myasthenia Gravis: Long-Term Follow-Up of the RINOMAX Clinical Trial. [PDF]

Eur J Neurol
Wu J, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundström P, Wickberg O, Frisell T, Brauner S, Piehl F.   +21 more
europepmc   +1 more source

Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now? [PDF]

Brain Sci
Rossini E, Leonardi L, Morino S, Antonini G, Fionda L.   +4 more
europepmc   +1 more source

Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study. [PDF]

Neurol Ther
Gu S, Li Y, Dong H, Yang H, Ma M, Li M, Yan C, Jia P, Wang Y, Qi G.   +9 more
europepmc   +1 more source

Management of refractory generalized myasthenia gravis with eculizumab during pregnancy and puerperium: a case report. [PDF]

Drugs Context
Karaman B, Tunçel R, Ekmekci Ö, Adatepe NU, Yüceyar N.   +4 more
europepmc   +1 more source

Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus. [PDF]

Front Neurol
Tsokkos T, Strataki E, Tzavella D, Zamba-Papanicolaou E, Kleopa KA, Zouvelou V.   +5 more
europepmc   +1 more source

Efgartigimod for generalized myasthenia gravis in the extreme elderly (≥80 years): a multicenter retrospective real-world study. [PDF]

Front Immunol
Hong Y, Yuan CW, Lu J, Kong PP, Huang SQ, Yang RY, Yuan ZH, Zhao HD, Jiang T, Chen J, Shi JQ.   +10 more
europepmc   +1 more source

Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis. [PDF]

CNS Neurosci Ther
Wang Y, Zhu W, Liu Q, Wen X, Xie N, Liu H, Geng Z, Jiang Y, Di L, Wang M, Lu Y, Duo J, Huang Y, Qian Y, Liu Q, Lv C, Da Y.   +16 more
europepmc   +1 more source

Correction: The short-term prognosis of very late onset generalized myasthenia gravis: a single-center retrospective cohort study. [PDF]

Front Neurol
Liampas I, Veltsista D, Batzikosta P, Lazarou L, Kefalopoulou ZM, Chroni E.   +5 more
europepmc   +1 more source